Skip to content
ZBIO·Nasdaq·US

Zenas BioPharma

Zenas BioPharma is a clinical stage global biopharmaceutical company that develops and commercializes immunology-based therapies for patients with autoimmune diseases. Its lead immunology and inflammation product candidate is obexelimab, a bifunctional monoclonal antibody that binds CD19 and FcγRIIb, and it also has programs ZB002 and ZB004.

Source: SEC 10-K Mar 11, 2025

Recent Activity

Updated Oct 17, 2026
–Zenas BioPharma presented new obexelimab data in IgG4-related disease at the 6th International Symposium on IgG4-Related Disease, with Phase 3 INDIGO open-label extension findings demonstrating sustained clinical activity of obexelimab.
–Zenas BioPharma announced inducement grants under Nasdaq Listing Rule 5635(c)(4).

Past updates are part of the Pro plan.

Thematic Position

ZBIO

Relationship Groups

Suppliers1
Customers1
Partners2
Licensing4
Competitors4

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariff
Trump Administration tariff on branded or patented drugs may raise imported drug costs
SEC 10-KMar 16, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.